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Cellerna i bukspottkörteln hos människa är normalt inte proliferativa, om dessa 
celler skadas är regenerationen snabb. Den bakomliggande mekanismen är inte 
känd men det innebär att pankreas funktion bibehålls. Forskning har ännu inte 
kunnat identifiera en definitiv stamcell i pankreas. I djurförsök är det möjligt att 
använda radioaktiva eller genetiska markörer för att följa cellinjer, vilket  inte är 
möjligt i humanforskning utan där används istället stamcellsmarkörer. Det finns 
därför ett behov att utveckla bättre teknik för att kunna följa, isolera och 
identifiera celler av samma ursprung (stamceller). Kvalitativ teknik skulle kunna 
möjliggöra kartläggning av ursprunget till celler, vilka härstammar från stamceller 
med mutationer, eftersom mutationer av mitokondriell-DNA ackumuleras 
natruligt i våra celler allt eftersom vi åldras.  
   
Eftersom proteinet cytokrom c oxidas kodas från mitokondriellt-DNA uppstår ofta 
defekter i cytokrom c oxidas om DNA:t är muterat. I den redovisade studien 
undersöktes muterade områden i normal pankreas där klonala grupper med celler 
kunde påvisas med hjälp av immunohistokemi avseende förekomsten av cytokrom 
c oxidas. Dessa grupper av celler har troligtvis samma ursprung. I studien försökte 
vi visa att dessa celler även uppvisade normal funktion, även vad gäller 
proliferationskapacitet. Undersökningen visade dock att celler med muterat 
mitokondriellt-DNA inte har normal funktion.  
  
Tekniken att spåra cellers delning och rörelse i human vävnad är användbar för att 
följa hur celler prolifererar och förflyttar sig i pankreas. Fortsatta studier inom 
området skulle kunna identifiera markörer för att påvisa förändringar i 






Background and aims: The human pancreas is normally proliferatively quiescent; 
however loss of cells gives a rapid regenerative response to restore a functionally 
healthy tissue mass. The mechanism for this is unclear and to date research has 
failed to identify a definitive pancreatic stem cell. Cell lineage analyses are 
possible in animals by labelling cells with radioactive tags or genetic markers, but 
this is not feasible in humans. Current human studies rely on stem cell markers, 
thus there is a need to develop a better technique to track, isolate and identify cells 
of related origin. Mitochondrial DNA mutations amass naturally within our cells 
as we age. Therefore, cells formed by division of a stem cell carrying mutated 
mitochondrial DNA should, given a qualitative assay, permit the progeny of this 
cell to be traced. 
Methods and results: Mitochondrial DNA mutations often result in a defect in the 
mitochondrial DNA-encoded protein cytochrome c oxidase, and can be identified 
using a histochemical stain. Individual mutant patches were studied by staining 
serial sections of normal pancreas. This revealed the presence of clonal units of 
cells, strong evidence that pancreatic cells within each patch are derived from a 
common progenitor. We tried to show that these cells are normal in synthetic and 
proliferative function, although this showed that the mitochondrial DNA mutated 
cells didn’t have normal synthetic function. However this did not negate our 
evidence of clonal proliferation. 
Conclusion: This novel means of tracing patterns of cell division and migration in 
human tissues is suitable for finding how cells proliferate and move in the human 
pancreas, and with continued work it might be useful as a marker for other 
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The aims of this project were to try to locate adult stem cells (SCs) in the human 
pancreas using mitochondrial DNA (mtDNA) mutations as a marker and to see if 
we could elucidate the clonal nature of normal pancreatic cells. In order to do this, 
we performed histochemical staining for cytochrome c oxidase (COX) expression, 
which is encoded by mtDNA. We firstly screened for the presence of COX-
negative (COX-ve) patches of cells, and after that we serially sectioned tissues to 
elucidate the patch architecture and patterns of cell migration. In parallel, we 
performed various studies to investigate whether COX mutation presents a 
selective advantage/disadvantage upon growth, survival or function of pancreatic 
cells.  Little is known about the location of pancreatic SCs and whether the 
progeny of these cells migrate in particular paths e.g. from exocrine ducts to islets. 
Studies in other tissues (e.g. gut) have successfully used this method to trace cell 
lineage relations by studying mtDNA mutations in individual laser-captured cells. 
The mitochondrial genome encodes 13 essential subunits of the respiratory chain 
and has remarkable genetics based on uniparental inheritance. Within human 
populations, the mitochondrial genome has a high rate of sequence divergence 
with multiple polymorphic variants. It has also been suggested that mtDNA 
mutations play a role in ageing and cancer, but the evidence for a causative role in 
these conditions is less clear. It is now known that mtDNA mutations occur in 
human colonic crypt SCs (Taylor et al. 2003, McDonald et al. 2006 [b], Greaves 
et al. 2006, Schon et al. 2003) and these mutations have been used to look at both 
the expansion of mutated clones in the colon and to provide a platform for lineage 
analysis in humans for really the first time.  
 
 
1.1 Histology of the human pancreas 
The pancreas is an elongated, tapered organ located at the back of the abdomen, 
behind the stomach. The right side of the organ, called the head, is the widest part 
of the organ and lies in the curve of the duodenum, the first section of the small 
intestine. The tapered left side, called the body, extends slightly upward and ends 
near the spleen, here called the tail. The pancreas has both endocrine and exocrine 
functions, but embryonically all the cells differentiate from the ductal epithelium. 
The endocrine cells migrate from the duct system and aggregate around capillaries 
to form isolated clusters of cells.  These clusters of cells are called the islets of 
Langerhans (referred from herein as islets) and are found scattered throughout the 
exocrine glandular tissue that consists of closely packed secretory acini (see figure 
1). There are approximately 1 million islets in a human pancreas, each composed 
of roughly 3000 cells of which 75 % are insulin producing β-cells (reviewed in 
Fellous et al 2006). The rest consists of α-cells (~5%), δ-cells (~20%) and PP-
cells (1%) cells.  
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a  b  
Figure 1. Haematoxylin-eosin stained normal pancreas tissue. (a) Overview, exocrine 
and endocrine. (b) Closer view of the exocrine part. 
 
 
1.2 Function of the human pancreas 
The exocrine system is made up of acinar cells lined with secretory glandular cells 
(pyramidal-shaped) that feed into a network of ducts; intercalated ducts, 
intralobular ducts and interlobular ducts that finally empty into the ampulla of 
Vater, situated in the duodenum. The production of functional enzymes is induced 
by gastrointestinal hormones such as cholecystokinin, acetylcholine and secretin, 
which are released when fatty acids and amino acids enter the duodenum. The 
function of the acinar cells is to produce lipase, chymotrypsin and 
carboxypolypeptidase for digesting proteins, pancreatic amylase for digesting 
carbohydrates and the main enzymes for digesting fat is pancreatic lipase, 
cholesterolesterase and phospholipase. The proteolytic digestive enzymes are 
produced in an inactive form (trypsinogen, chymotrypsinogen and 
procarboxypolypeptidase) and become activated upon contact with enzymes in the 
intestinal tract, known as enterokinases. The intestinal mucosa secretes 
enterokinases as it comes in contact with chyme. Enterokinases lead to activation 
of trypsin, which in turn activates the other protein degrading enzymes. These 
function to prevent self-digestion of the pancreas, in addition to trypsin inhibitor, 
which is produced by the glandular cells. Acute pancreatitis can occur if these 
security controls fail and trypsinogen becomes activated at the sight of production 
(Guyton & Hall 2006 [a].). 
 
The endocrine component constitutes approximately 1% of the mass of the 
pancreas, and regulates glucose storage and usage via secretion of insulin 
produced in the β-cells, glucagon produced in the α-cells, somatostatin made in 
the δ-cells (inhibits the endocrine pancreas) and pancreatic polypeptide produced 
in the PP cells (which inhibits the exocrine pancreas). Reduction in β-cell number 
will inevitably give rise to diabetes, one of the most common diseases in the 
western world. Diabetes occurs in two varieties, although both are caused by a 
relative lack of insulin to meet peripheral demands. Type I diabetes is due to an 
immune-mediated destruction of pancreatic insulin producing β-cells, whereas in 
type II the endocrine pancreas produces insufficient amounts of insulin to 
compensate for peripheral insulin resistance. The rate of normal pancreas 
proliferation declines dramatically with age. The pancreatic cells, although 
essentially quiescent in the normal adult, have a great capacity for proliferation in 
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response to injury; therefore it is reasonable to assume that the expression of SC 
markers will be greater in diseased pancreas. It is the renewal of β-cells that is of 
primary interest for the treatment of diabetes, a disease that currently afflicts 
around 200 million people worldwide (reviewed in Fellous et al. 2006). 
 
 
1.3 Stem cells 
The key properties of SCs, namely indefinite self-renewal and multilineage 
potential were first recognized in the bone marrow (reviewed in Burkert et al. 
2006). In most tissues, SCs are rare (Reya et al. 2001). The ability of a single cell 
to give rise to a large family of descendants (clonogenicity), containing all the 
lineages normally found in that cells tissue of origin is often considered a 
reasonably robust proof of “stemness”. To achieve self-renewal, on average, each 
SC division must give rise to one replacement SC and one transit amplifying cell 
(TAC) by asymmetric cell division. TACs are committed to differentiation and 
with each successive division they lose their proliferative potential (reviewed in 
Burkert et al. 2006). Eventually, TACs give rise to terminally differentiated cells 
(TDCs) (see figure 2) which are mitotically inactive. TDCs are the cells that form 
the bulk of the tissue e.g. in case of the small intestine, these comprise the 




Figure 2. Diagram showing the path of differentiation of a stem cell (Burkert et al. 2006).  
In most renewing systems, a cell hierarchy can be recognized in which a few self-
renewing SCs give rise to a limited number of transit amplifying cells (TACs). TACs have 
limited proliferation potential and eventually give rise to reproductively sterile terminally 
differentiated cells. 
 
SCs are located in deterministic environments called niches (Fr. recess), 
composed of mesenchymal cells and extracellular matrix factors (Alison et al. 
2006), wherein regulatory pathways such as Wnt/β-catenin, PTEN, Notch and 
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Hedgehog have a tight control on their renewal and maturation processes. Due to 
the hierarchical migratory nature of differentiating TACs, the SC niche is most 
likely to be situated at the origin of cellular flux, as interactions between the SCs 
and the niche cells are vital to the self-renewal process. For example, in a tissue 
like the small intestine, the niche is found close to the crypt base which is at the 
origin of the flux (reviewed in Burkert et al. 2006).  
 
 
1.4 Cancer stem cells 
A tumour’s capacity for growth and propagation is suggested to be dependent on a 
small subset of cells within the tumour, the so-called cancer stem cells (CSCs) (Li 
et al. 2007). Cells that can re-initiate tumour growth in an immunocompromised 
animal are operationally defined as CSCs (Olempska et al. 2007). Reya et al. 
(2001), state that cancers of the haematopoietic system provide the best evidence 
that normal SCs are the targets of transforming mutations, and that cancer cell 
proliferation is driven by CSCs.  They propose that newly arising cancer cells 
utilise the machinery that is normally expressed by SCs for self-renewal (Reya et 
al. 2001). There is also evidence that many of the pathways that classically are 
dysregulated in cancer, such as Wnt, Shh and Notch, may regulate normal SC 
behaviour during development (Reya et al. 2001). Therefore understanding SC 
self-renewal and its regulation is very important as this can give an understanding 
of the regulation of cancer cell proliferation, which can be seen as a 
disease/dysfunction of unregulated self-renewal (Reya et al. 2001). The existence 
of CSCs was first documented in haematological malignancies (Li et al. 2007) 
and was subsequently discovered in several solid tumours, including breast (Al-
Hajj et al. 2003), prostate (Collins et al. 2005), brain (Singh et al. 2003), liver 
(Suetsugu et al. 2006), lung (Dome et al. 2006), melanoma (Grichnik et al. 2006) 
and colon (Guzman et al. 2002).  
 
It has been shown that CSCs in some tumour types are more resistant to standard 
chemotherapeutic agents (Guzman et al. 2002). This might explain why 
chemotherapy can result in tumour shrinkage, but also why most tumours recur, 
implying that treatments that specifically target the CSC population may be more 
effective in treatments to eradicate solid tumours (Li et al. 2007). 
 
Many markers such as CD44, CD133 and members of the Wnt signalling pathway 
including β-catenin and Tcf-4, have been proposed as markers of SC in several 
tissues (reviewed in Alison et al. 2006), although to date no definitive evidence of 
this has been documented in the adult human pancreas. CD133 is expressed by 
cells in solid tumours of the brain, prostate, colon and liver and is now 
increasingly accepted as a CSC marker, according to Olempska  et al. (2007). 
CD44 is a cell surface glycoprotein involved in cell-cell and cell-matrix 
interactions. Increased expression of CD44 and its variants has been implicated in 
the transformation and progression of many malignancies (Burkert et al. 2006, 





1.5 Stem cells in the pancreas 
Though the existence of a specific self-renewing SC within the pancreas is still far 
from clear, a surprising variety of cells within the pancreas can differentiate 
towards a β-cell phenotype, with evidence that the ductular cells, periductular 
mesenchymal cells and β-cells themselves can all give rise to new β-cells. There is 
also evidence of an extra-pancreatic location of the pancreatic SC with evidence 
that cells in both the bone marrow and liver can differentiate and contribute to 
pancreatic β-cell mass (reviewed in Fellous et al. 2006).  
 
In terms of pancreatic morphogenesis, the most probable location of pancreatic 
progenitor cells is the ductal epithelium, as it retains the ability to give rise to all 
the differentiated cell types of the pancreas. Data from the laboratory of Bonner-
Weir et al. (2000) supports this suggestion, as they have shown that mature ductal 
cells can regress or dedifferentiate to become the main source for pancreatic 
growth and regeneration. As ductal cells account for about 80% of all pancreatic 
cancers, it seems likely that the CSCs will originate from the duct. Numerous 
studies have highlighted that ductal cells from mouse (Peck et al. 2002), rat (Kim 
et al. 2004) and human pancreas (Bonner-Weir et al. 2000) can generate all the 
pancreatic endocrine cell types under controlled in vitro conditions, but the 
identity of any multipotential SC is still lacking. Furthermore, the islets originate 
from the ductal epithelium and numerous studies in murine and human models 
have reported the differentiation of insulin producing cells in vitro and in vivo 
from cultured pancreatic ductal cells. Dor and colleagues (2004) suggest that new 
β-cells arise from self-duplication of pre-existing β-cells and that there are no SCs 
in the mouse pancreatic islets, although they didn’t rule out the presence of a 
pancreatic SC population as they stated “the stem cells themselves may express 
insulin” (Dor et al. 2004). This is opposed by Oshima et al. (2007), who observed 
the differentiation of intra-islet progenitor cells into insulin producing cells in 
vitro, and therefore suggest the islets as a possible niche for SC. A considerable 
number of studies propose that islet cells regenerate from progenitor cells residing 
in the islets (Yalniz & Pour 2005). Hunziker and Stein (2000) reported a subset of 
nestin-expressing hormone negative cells within the pancreatic islet of a 4-week 
old mouse and proposed that these cells represent multipotential stem/precursor 
cells for the differentiated pancreatic endocrine cells. Subsequently, Zulewski et 
al. (2001), noted similar cells with an extended proliferative capacity, not only in 
the islets of the adult rat and human pancreas, but also in large, small and 
centrolobular ducts of the rat pancreas (Zulewski et al. 2001). The ability of 
insulin secreting β-cells to divide is recognized, but there is no universally 
accepted evidence for their derivation from adult pancreatic SCs (Bonner-Weir et 
al. 2000).  
 
In addition to an intrapancreatic location of pancreatic progenitors, there has been 
a few suggestions of extra-pancreatic sources. Bone marrow SCs can seemingly 
abandon or alter their intrinsic programming for defined 
haematopoietic/mesenchymal lineage differentiation, and engraft and contribute to 
functional adult lineages within non-haematopoietic tissues, including the 
pancreas (reviewed in Fellous et al. 2006). Haematopoietic SCs in the bone 
marrow has been considered the potential source of pancreatic SCs, as they have 
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been found to reduce hyperglycaemia in diabetic mice after differentiation into 
insulin producing cells in vitro followed by cell transplantation (Voltarelli et al. 
2007). Ianus et al. (2003), also claim that bone marrow cells are capable of 
transdifferentiating to produce fully functioning pancreatic β-cells. Other potential 
sources that have been proposed are mesenchymal SCs in the bone marrow (Sordi 
et al. 2005), spleen (Kodama et al. 2003) and liver (Grompe 2003, Shen et al. 
2003, Wolf et al. 1990).    
 
Zhang et al. (2005) showed that human foetal cells could differentiate to produce 
insulin, although this was a low production of insulin and the cells lacked specific 
transcription factors. Other recent studies claim that there are no progenitors in the 
pancreas (Brennand et al. 2007, Teta et al. 2007), as discussed later.  All in all this 
gives us a variety of possible locations of SCs in the pancreas, but as said before, 
no definitive location has yet been found. 
 
The prospect of curing diseases by replacing old, mutated SCs with new, healthy 
ones is very appealing (Bonner-Weir et al. 2000). Pancreatic cancer is usually 
diagnosed in an advanced state, which in addition with the lack of any effective 
therapies gives it the worst prognosis of any malignancy. Only 3% of patients 
have a 5 year expected survival (Li et al. 2007) and therefore cancer of the 
pancreas is the fourth leading cause of death in industrialized countries 
(Niederhuber et al. 1995, Olempska et al. 2007), thus highlighting the need for an 
early diagnosis (Niederhuber et al. 1995). 
 
 
1.6 Stem cell markers 
SC in the pancreas remain unidentified due to a lack of reliable markers of 
undifferentiated cells. But many different factors have been proposed as markers 
of pancreatic SCs including transcription factors Ngn3, Pax4, Nkx2.2, Nkx6.1, 
Pax 6 and Islet1, which are required for β-cell development. And indeed, 
according to Bonner-Weir and Sharma (2002) these factors are expressed in ducts 
and appear to be responsible for the rapid islet neogenesis that occurs after a 90% 
partial pancreatectomy in the rat (Bonner-Weir and Sharma 2002). Nestin has also 
been proposed as a pancreatic SC marker although this is controversial since 
nestin is also expressed by fibroblast like cells in the pancreatic stroma (Bonner-
Weir and Sharma 2002). Suzuki et al. (2004)  proposed c-Met as a marker of SC 
in the pancreas. However β-cells derived in vitro from these c-Met positive 
lineages were not fully functional and following transplantation of the c-Met-
positive cells only very low levels of donor-derived pancreatic endocrine cells 
were observed. Other suggested pancreatic SC markers are the ABC transporters, 
such as ABCG2 and MDR-1, which are also expressed by nestin-positive islet-
derived progenitor (NIP) cells (reviewed in Alison et al. 2006).  
 
1.6.1 Label retaining cells (LRCs) 
The slow-cycling nature of SCs allows them to be identified in animal models in 
tissues that undergo constant proliferation such as the gut and skin, following 
labelling with a marker of the cell cycle such as bromodeoxyuridine (BrdU) or 
triated thymidine (3HTdR) (reviewed in Burkert et al. 2006). If one can label a 
cell with a specific marker, then all the cells subsequently borne from this cell will 
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carry the marker and can thus be identified as offspring of the original labelled 
cell. Cells in the S-phase of the cell cycle use thymidine exclusively for the 
synthesis of DNA. Molecules of thymidine can be radioactively labelled to make 
3HTdR or alternatively an analogue of thymidine in the form of BrdU can be used 
(Braun & Watt 2004). Thus all cells that have incorporated the labelled compound 
are recognised by either autoradiography in the case of 3HTdR, or by antibody 
detection of BrdU (Alison et al. 1997). With every cell division the label is diluted 
into daughter cells and so slowly cycling SCs can be LRCs. According to the 
Cairns immortal strand hypothesis SCs have template DNA strands that are 
always retained by the SC during asymmetric division (Cairns 1975). Another 
technique involves the use of labelling with a retrovirus containing the ‘E coli β-
galactosidase gene’. In this method, a retrovirus is used to incorporate the ‘E coli 
β-galactosidase gene’ into synthesising DNA and again all daughter cells will 
carry the label. As SCs in these tissues do not divide as rapidly as their transit 
amplifying progeny, the SCs retain their label, hence becoming ‘label retaining 
cells’ (Braun & Watt 2004, Alison et al. 2006). These techniques are only suitable 
for animal studies of cell lineage analyses as it would be highly unethical to use 
these techniques in human studies. As our study involves human tissue, but we 
still wanted to label and trace cells of common origin, we therefore applied a 
technique that utilises the random and natural accumulation of mutations in the 
mitochondrial genome.  
 
 
1.7 Mitochondria and mtDNA  
Mitochondria are membrane enclosed organelles, the energy producing 
components in all cells. The mitochondrion is a double-membraned organelle and 
is easily recognized due to the invaginations of the inner membrane. Mitochondria 
are present in all areas of each cell’s cytoplasm though are more concentrated in 
those portions of the cell that are responsible for the major share of its energy 
metabolism. The total number of mitochondria per cell varies from less than a 
hundred up to several thousand, depending on the amount of energy required by 
the cell. Being the powerhouse of cells means conversion via oxidative 
phosphorylation of the reduced form of nicotinamide adenine dinucleotide 
(NADH), flavin adenine dinucleotide (FADH) and nicotinamide adenine 
dinucleotide phosphate (NADP) into adenosinetriphosphate (ATP). ATP is the 
energy form used by the body for various physiological functions that are 
necessary to maintain and propagate life such as active transport of molecules 
across cell membranes, cell division and growth and various synthetic reactions 
that create hormones, cell membranes and many other essential molecules of the 
body. 90% of the carbohydrates utilized by the body are converted in to ATP via 
their digestion to glucose, fructose and galactose, with glucose representing 
approximately 80% of these. Glucose can diffuse into cells, but its uptake into 
cells is increased up to ten or more times more when insulin is secreted. In the 
absence of insulin the supply of glucose that is taken up by cells is negligible, 
with the exception of the cells in the brain and liver (Guyton & Hall 2006 [b].)  
Impairment of mitochondrial function is intrinsically related to diabetes. Studies 
have observed a reduced rate of ATP synthesis in subjects with a family history of 
diabetes prior to the onset of impaired glucose tolerance (Petersen et al. 2004), 




The presence of mtDNA results in the mitochondria being a self-replicative 
organelle, with mitochondrial division occurring independently of cell division 
following nuclear DNA replication. MtDNA is a maternally inherited circular 
double-stranded mtDNA composed of 16.5kb base pairs in humans. MtDNA 
comprises less than 1% of the total cellular nucleic acid (Cottrell & Turnbull 
2000), although despite this mtDNA is essential for the normal survival of the 
mitochondria and hence the cell. MtDNA encodes 13 polypeptides, 22 tRNAs and 
2 rRNAs, all components of the respiratory chain/oxidative phosphorylation 
system (Anderson et al. 1981) (see figure 3). Dysfunctional mtDNA results in an 
aberrant respiratory chain. At a single cell level, this defective oxidative 
phosphorylation becomes apparent when the level of mutated mtDNA exceeds 
70% of the total mitochondrial population (Cottrell & Turnbull 2000). In older 
studies, the proposed percentage for the mutated phenotype to emerge is even 
higher, 85% according to Aspnes et al. (1997). MtDNA mutations frequently 
occur as mtDNA differs from normal DNA in its protective mechanisms. For 
example, mitochondria lack protective histones and have few and inefficient DNA 
repair mechanisms. This, in addition with the high rate of mitochondrial turnover 
and the exposure of mtDNA to free oxygen radicals from the electron transport 
chain makes the mtDNA more prone to somatic mutations which increase in 
incidence and accumulate with age (Brierley et al. 1997). MtDNA is estimated to 
be 16-fold more susceptible than nuclear DNA to oxidative modifications (Richter 
et al. 1988).  However, mtDNA mutations are generally phenotypically passive, 
which could be crucial to the conclusions drawn from this study.  
 
 
Figure 3. Map of the mitochondrial genome.  
 
The electron transport chain, also called the respiratory chain, is an integral part of 
the inner mitochondrial membrane and consists of ATP synthetase, two mobile 
electron carriers and four electron-transporting protein complexes designated I-IV 
(Ritter 1996) (see figure 4). Cells deficient in COX, usually due to a truncating 
mutation, but with normal succinate dehydrogenase (SDH) activity are excellent 
biomarkers of mtDNA defects. COX is a large transmembrane protein which 
constitutes the fourth and last complex and also the second mobile electron carrier 
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of the respiratory chain. It receives an electron from each of four cytochrome c 
molecules (cytochromes are heme proteins), and transfers them to one oxygen 
molecule, converting molecular oxygen into two molecules of water. This redox 
reaction accounts for a significant portion of the water that is eliminated from the 
human body each day.  In the process, it translocates four protons, helping to 
establish a chemiosmotic potential that the ATP synthase (seen as the fifth 
complex) then uses to synthesize ATP. Among the many classified mitochondrial 
diseases, those involving dysfunctional COX assembly are thought to be the most 
severe (Pecina et al. 2004). Complex IV is designed to prevent partially reduced 
O2 from escaping, although some oxygen-containing free radicals do break away. 
Antioxidants and enzymes play a key role in protecting the body from these 
reactive agents (Ritter 1996). The three major catalytic subunits of COX (COX I, 
II and III) are encoded by mtDNA and so COX defiency can be used as a marker 
for mtDNA mutations. SDH on the other hand is entirely encoded by nuclear 
DNA and so is independent of mtDNA mutations. SDH is a enzyme functioning 
at the crossroads of the citric acid cycle (TCA) also called the Krebs cycle and the 
electron transport chain, and is the only TCA cycle enzyme that is membrane-
bound. The enzyme complex is a heterotetramer divided into three domains: 
SDHA, the catalytic domain; SDHB, the electron transfer subunit; SDHC/SDHD, 
the dimeric membrane anchor that contains β-type heme (Ritter 1996). 
 
Figure 4. The respiratory chain, its connection to the TCA and how the subunits are 
encoded. 
 
Different studies have shown that a characteristic feature of ageing and mtDNA 
disease is the presence of COX deficient cells in tissues, such as skeletal and 
cardiac muscle (Müller-Hoecker 1989, Müller-Hoecker et al. 1989, Müller-
Hoecker et al. 1992, Brierley et al. 1997, Aspnes et al. 1997,  Cottrell & Turnbull 
2000).  
 
If COX activity is absent, SDH activity should remain as both complexes are 
encoded by different DNA i.e. mitochondrial and nuclear DNA, respectively. It is 
possible to utilise this fact to detect cells that have a mutation in COX. In a dual 
COX/SDH assay, sections are incubated first in the COX-detecting medium and 
any cells that fail to become saturated with the brown reaction product, i.e. COX 
deficient cells, are turned blue by subsequent incubation in the SDH-detecting 
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medium. This method facilitates the visualisation of COX negative cells (for more 
information see ‘materials and methods’). 
 
 
1.8 MtDNA mutations in the human colon 
MtDNA mutations have been extensively studied in the human colon. Taylor et 
al. (2003), studied mtDNA mutations in COX deficient cells. The three major 
catalytic subunits of COX are encoded by mtDNA as mentioned above, so 
therefore COX deficiency can be used as a marker of mtDNA mutations (Taylor 
et al. 2003). The results of this study showed that human colonic crypts have a 
mixed phenotype. Ribbons of cells were observed to extend the entire length of 
the crypt from the site of the SCs in the crypt base, up to the intestinal lumen (see 
figure 5) (Taylor et al. 2003). Ribbons of COX-ve epithelial cells were frequently 
accompanied by ribbons of cells with a wild type phenotype i.e. no mutation in 
COX. Therefore, in this instance in each crypt there are at least two SCs, one with 
a COX deficiency due to mtDNA mutation, and the other expressing COX 
normally. A further study investigating mtDNA mutations in human colonic 
crypts was carried out by Greaves et al. (2006). In this study the sequences of the 
mitochondrial genome of COX-ve and COX-positive (COX+ve) cells were 
deduced, following laser microdissection of individual cells within patches of 
either phenotype. This was to identify whether COX-ve cells contained an 
identical mtDNA mutation, and were thus clonal in origin. Sequencing of these 
cells showed that the COX-ve cells within a single patch did indeed display 
identical mutations and are thus daughter progeny, derived from a clonally 
expanding SC (Greaves et al. 2006). Furthermore, it was demonstrated that COX-
ve cells within neighbouring crypts expressed identical mtDNA mutations. The 
observation that identical mtDNA mutations are present in both arms of a 
bifurcating crypt confirmed that crypt fission is the process by which colonic 
crypts divide and spread (McDonald et al. 2006 [b], Greaves et al. 2006). The 
techniques used in this study can be used to investigate cellular behaviour in other 










c  d                
 
Figure 5. From Taylor et al 2006. (a) Normal COX activity (brown) in colonic crypts 
following a dual COX and SDH histochemistry. (b) COX deficient colonic crypts (blue) 
among crypts with normal COX activity (brown). (c) Partial COX deficiency in colonic 
crypt (arrow) following a dual COX and SDH histochemistry. (d) 3D representation of 59 
serial sections, showing ribbons of cells that are derived from either a COX+ve SC 





In order to explore the possibility of a stem lineage within the human pancreas we 
will, in this study, take advantage of mutations that occur within the mitochondrial 
genome. If long-lived stem cells exist they will acquire a sufficient degree of 
mutated mtDNA to be recognised morphologically. If such cells produce a large 






3. MATERIALS AND METHODS 
3.1 Ethical approval to use human tissue 
Ethical permission was granted from the Redbridge and Waltham Forest Local 
REC on 9th May 2006 to use human tissue from the Royal London Hospital REC.  
Permission was extended on 15th January 2007 to use tissue from the 





Immunohistochemistry is the only technique which can identify an antigen in its 
tissue or cellular location i.e. in situ. The definition of immunohistochemistry is 
the use of a labelled, and thus identifiable, antibody as a specific reagent to 
localise with high affinity and avidity to a specific tissue constituent (antigen) in 
situ (Polak & Van Norden 1997).  
 
Immunohistochemistry using antibodies that specifically detected COX subunits 
was applied in this study to visualise patches of COX-ve cells within serial 
sections of normal human pancreas. Immunohistochemistry was also used to 
detect the expression of various antigens by COX-ve cells, to ensure that these 
cells were otherwise phenotypically normal. For all immunohistochemical 
protocols, appropriate positive and negative controls were used.  Prior to routine 
use of any newly acquired antiserum, a serial dilution was tested on positive 
control sections of fixed tissue in order to establish optimal dilution for each 
antibody.  Normal sera and secondary antibodies were used at the highest 
concentration recommended by the manufacturer.  To eliminate background 
staining, the primary antibody was further diluted, or if unsuccessful, a serial 
dilution series of the secondary antibody was performed. 
 
3.2.1 Tissue embedding and sectioning 
Formalin-fixed, paraffin-embedded tissue blocks were obtained from the archives 
of the Royal London Hospital and Hammersmith Hospital. Embedded tissue 
blocks were sectioned at 4µm using a Leica sledge microtome, and then placed on 
a 57oC water bath to remove creases.  Tissue sections were placed on glass 
microscope slides (Thermo Shandon COLORFROST®) and dried overnight at 
37oC and then kept in sealed slide boxes. Tissue sections were cut by the 
Histopathology service, ICMS. 
 
3.2.2 Dewaxing and blocking of endogenous peroxidases- paraffin sections 
Tissue sections were deparaffinised/dewaxed by a 6 minute immersion in sulphur 
free xylene (BDH) followed by a 2-minute immersion in absolute ethanol and 1-
minute in 70% ethanol. This was followed by a 15 minute immersion in 30% 
hydrogen peroxide (BDH) in methanol to block for endogenous peroxidases.  
Tissue sections were re-hydrated by 2 minute incubations in decreasing ethanol 
concentrations (100%, 100%, 95%, 70%) then rinsed in cold tap water and 




3.2.3 Immunohistochemical staining protocol 
It is vital to ensure that tissue sections do not become dry during 
immunohistochemistry. Antigen retrieval was performed by microwave treatment 
in preheated sodium citrate buffer (10 mmol/L; pH 6, Fisher Chemicals) for 20 
minutes at 700W, this is to destroy the cross-links (hydroxy-methylene bridges) 
that form during formalin fixture of tissues (34). Sections were then rinsed in tap 
water, and washed in PBS. Slides were then put into sequenzers (Shandon 
Sequenza, Thermo Electron Corporation) and rinsed with PBS (Sigma) containing 
0.01% Tween-20. A mouse monoclonal  antibody specific  to human  COX 
complex IV subunit I (Invitrogen Molecular Probes, USA) was used in 
combination with a staining kit, Super Sensitive Polymer-HRP Detection System 
(BioGenex, USA). ‘Power block’ from the kit was diluted 1 in 10 in H2O and 
applied to slides for 10 minutes and then the COX antibody solution was added, 
diluted in PBS at a 1:500 concentration. Thereafter, the rest of the kit was applied 
in accordance with the manufacturer’s recommendations (Super Enhancer 
solution for 20 minutes, followed by PBS rinse, HRP for 30 minutes, rinse with 
PBS, then finally an application of DAB chromogen solution to develop staining, 
followed by a final rinse in tap water).  
 
Table 1. Range of antibodies that were used in combination with the kit. The last four 
antibodies were stained courtesy to Prof Turnbull and Dr Ziabrevain, University of 
Newcastle. 








Ki-67 Human Mouse monoclonal 
IgG 
1:50 Novacastra 
Porin Human Mouse monoclonal 
IgG 
1:400 Invitrogen 










Human Mouse monoclonal 
IgG 
1:100 Invitrogen 







3.2.4 Counterstaining protocol 
Sections were counterstained with Coles haematoxylin (Pioneer Research 
Chemicals) for 1 minute after a bath in Copper (II) sulphate for 2 minutes (VWR 
International Ltd.). Then slides were rinsed thoroughly in cold tap water before 
immersion in acid alcohol (1% v/v concentrated HCl in 70% ethanol) for 10 
seconds to get rid of excess haematoxylin. This was followed by immersion in 
Scott’s tap water (30mM LiCO3, 160 mM MgSO4) for 20 seconds to fix the 
staining before rinsing in cold water for a final time. Sections were then rapidly 
rehydrated using graded ethanol (70% 15 sec, 93% 30 sec, 100% 30 sec, 100% 30 
sec) before being immersed in xylene (BHD), finally sections were mounted using 
Permafluor mounting medium (Thermo Electron Corporation).  
 
3.2.5 Serial Sectioning and Immunohistochemistry 
Initial staining was performed on 30 blocks of normal human pancreas, and those 
containing patches of COX-ve cells were selected for further analyses (n=5). 
From each block, 50 x 4µm serial sections were cut. Immunohistochemistry for 
COX was performed on each section to allow visualisation of  COX-ve patches of 
cells. This technique permitted us to envisage patch size, shape, phenotype of 
cells within the patch, possible direction of flux and interaction with 
morphological structures within the pancreas i.e. do patches of cells appear to 
emerge from or interact with the pancreatic ducts? 
 
3.3 Immunofluorescence staining 
3.3.1 Immunofluorescent double label staining – paraffin sections 
As initial staining for COX revealed that the majority of COX-ve cells formed 
patches within the exocrine pancreas, further staining was performed where COX 
immunoreactivity was combined with amylase antigen expression, both of which 
were detected using fluorescence immunohistochemistry.  For this technique, 
deparaffinisation of tissue sections and microwave antigen retrieval were 
performed as above. Non-specific antibody binding was minimized using normal 
swine serum (DAKO) in a 1:25 dilution for 15 minutes. The antibodies were 
applied in the following sequence, first primary; first secondary; second primary; 
second secondary (refer to tables 1 and 2). All antibodies were diluted in PBS pH 
7.4 and incubated for 1 hour at room temperature, with 3 x 5 minute washings in 
PBS between each layer of antibody.  A second block for non-specific antibody 
binding was done after the incubation with the first secondary antibody. After the 
final wash, the slides were mounted under glass coverslips using Vectashield 
Hardset with DAPI mounting medium (Vector Laboratories). 
 
3.3.2 Immunofluorescent double labelling staining – frozen sections 
The frozen sections were removed from the freezer and allowed to dry completely 
before staining. Antigen retrieval was performed by immersing slides in cooled 
ethanol 100% for 20 minutes. Slides were then washed in cold PBS for 5 minutes 
before washing in PBS at room temperature and blocking for non-specific binding 
using protein block (Dako Cytomatikon, Denmark). The antibodies were applied 
in the following sequence, first primary; first secondary; second primary; second 
secondary (refer to table 1 and table 2). All antibodies were diluted in PBS pH 7.4 
and incubated for 1 hour at room temperature, with 3 x 5 minutes washing in PBS 
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between each layer of antibody.  A second block for non-specific antibody 
binding was done after the incubation with the first secondary. After the final 
wash, the slides were mounted under glass coverslips using Vectashield Hardset 
with DAPI mounting medium (Vector Laboratories). 
 
Table 1. Primary antibodies used in the immunofluorescence protocols 
Antibody Specificity Species Dilution Source 
Anti-Cox Human Mouse monoclonal IgG 1:500 Invitrogen 
Amylase Human Rabbit monoclonal IgG 1:50 Sigma 
 
 














555 conjugated goat 
anti-rabbit IgG 
Cy 3 Alexa 
fluor 
 
As the fluorescent stains are light sensitive the slides were kept in the dark during 




3.4 Principles of enzyme histochemistry 
It is not possible to isolate cells with mutant DNA from immunostained paraffin 
pancreas sections, thus another technique is required to detect COX activity in 
frozen pancreas. Succinate dehydrogenase (SDH) is entirely encoded by nuclear 
DNA, therefore independent of mtDNA mutations. In the dual COX/SDH double 
stain, when COX activity detected as a brown colour is absent nuclear SDH 
activity remains, staining blue ( McDonald et al. 2006 [a]). This is another method 
of visualising COX-ve cells in frozen tissue allowing subsequent laser capture 
microdissection of individual cells. This method uses diaminobenzidine 
tetrahydrochloride (DAB) as an electron donor in the respiratory chain at the level 
of cytochrome c, which is then subsequently reduced by COX. Oxidation of DAB 
generates an insoluble indamine polymer. This reaction can only take place if 
COX is present to oxidise cytochrome c allowing it to accept electrons from 
(DAB). The SDH medium uses NitroBlue tetrazolium (NBT) as an electron 
acceptor in the electron transport chain at the level of SDH. When it is reduced, 
NBT creates an insoluble blue formazan.  Phenazine methosulphate (PMS) is 
required to act as an electron carrier between SDH and NBT, thus acting as a 
catalyst and accelerating the rate of reaction (Mc Donald et al. 2006 a).  
 
3.4.1 COX/SDH histochemistry staining protocol 
Serial sections of 20µm thick frozen human pancreas were cut and mounted on 
polyethylenenaphthalate slides (Leica Microsystems UK). Sections were first 
 
 20
incubated in COX incubation medium (100µM cytochrome c, 4mM DAB, 
20µg/ml catalase in 0.2M phosphate buffer pH 7.4) for 50 min. Sections then 
underwent a 3 x 5 minute wash in PBS followed by incubation in SDH medium 
(130mM sodium succinate, 200µM PMS, 1mM sodium azide, 1.5mM NBT in 
0.2M phosphate buffer pH 7.4) for a further 45 minutes.  This was followed by a 
further 3 x 5 min wash in PBS followed by dehydration in graded ethanols (70%, 
95%, 100%) for 2 minutes each, followed by a final 100% ethanol for 10 minutes.  
Sections were cleared in 2 changes of Histoclear (National diagnostics, USA) then 
air-dried for 1 hour. All washes were in PBS pH 7.4 and incubations at 37oC. 
 
 
3.5 Visualization of slides 
Tissue sections stained using DAB were visualized using a Nikon Eclipse E600 
multi-headed microscope. Fluorescently stained slides were viewed using an  
Olympus BX61 fluorescence microscope/ Leica DM5000 fluorescence 
microscope (Leica Microsystems UK).  Fluorescent images were captured using 
Elpac QImaging MicroPublisher 5.0. All images were captured at 72 pixels/inch 
using the image analysis software ‘Qwin’. Imaging processing was performed 






4.1 Results of COX immunohistochemistry 
Immunohistochemistry for COX complex IV subunit I was initially performed on 
several tissue blocks (n=30) to identify COX deficient cells in the normal human 
pancreas. Based upon this 5 blocks were then selected which revealed the 
presence of COX-ve patches distributed throughout normal pancreas (see figure 6 
a-c). Interestingly these patches were often in close contact with the epithelial 
ducts (see figure 6 a and c). Staining revealed that in most patches there are a 
small number of COX+ve cells dispersed throughout the mutant patches (see 
figure 6 e). It is possible that these cells are a distinct lineage from those COX-ve 
cells in the patch e.g. stellate cells, and thus are of a different clonal origin. Also 
we could see some cells with very high COX expression (see figure 6 d), these 
generally occurred throughout the exocrine pancreas, outwith the COX-ve patches 





a b  
c d  
 
e  
Figure 6. Photomicrographs of immunohistochemistry for COX Complex IV subunit I in 
normal pancreas. (a-c) show patches of mutated cells in the exocrine pancreas and often 
near ducts (arrow, c). (d) Some cells have very high COX expression. (e) Shows the 




4.2 Results of COX immunohistochemistry on serial sections of 
human pancreas.  
Immunohistochemistry for COX complex IV subunit I was performed on 50 serial 
sections of human pancreata (n=5: aged 21, 21, 33, 34, 72) that had previously 
been selected for the presence of patches to observe size, shape and migration of 
the COX-ve colonies through the tissue. Staining revealed that the size and shape 
of the patches varied considerably (see figure 7 and 8). Movement of the patch 
could be seen and was followed throughout the series. Most patches was present 
for about 20 serial sections and did change shape, perhaps reflecting the 
sectioning through a more or less spheroid patch. Each patch was composed of 
numerous acini and individual acini that were only partially affected were never 
observed. Often patches appeared to be infiltrated by whole acini that were 





Figure 7. Photomicrographs of immunohistochemistry for COX complex IV subunit I on 


















Figure 8. Photomicrographs of immunohistochemistry for COX complex IV subunit I on 
50 serial sections of human pancreas. Here a patch is followed for 20 serial sections. 
Arrows show presence of whole acini that are COX+ve. 
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4.3 Results of immunohistochemistry for Ki-67 
Immunohistochemistry for Ki-67, a cellular marker of cell proliferation, was 
performed on human pancreas sections. A COX-ve patch was identified, then on 
the following sequential section, the same tissue was stained for Ki-67. The COX-
ve patch stained negative for Ki-67, suggesting that these COX-ve patches are non 
hyperplastic. 
 
a  b  
Figure 9. Immunohistochemistry for Ki-67 (a) Stained for COX and 9b) stained for Ki-
67. No sign of over-expression of Ki-67 was seen in the COX-ve patch (circled).
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4.4 Results of immunofluorescent histochemistry 
An immunofluorescent dual stain was performed on human pancreas sections for 
COX/amylase to test if patches of COX mutated cells are otherwise normal i.e.  
produce amylase. Normal pancreas was stained as a control and can be seen in 
figure 10. We observed patches that produced less amylase, which therefore 
implied that the synthetic function was reduced in the COX-ve cells making up a 
patch (see figure 11 and 12). However, interestingly we also found patches that 
were a mixture, containing cells that were COX-ve but produced amylase to the 
same degree as the surrounding COX+ve cells and one part where there was 
reduced for amylase expression (see figure 13). When viewed using the aqua-
channel of the microscope, the cell morphology of the patches is not different to 
that of the surrounding cells (see figure 14) also confirming that the patches are 
not an artefact of the staining protocol as they cannot be viewed at other 
wavelengths. We also observed strongly immunoreactive cells by this method (see 
figure 15), interestingly these do not express amylase. Another interesting finding 
was that the ducts were COX+ve, COX-ve or a mixture of both (see figure 16).          
   
    Amylase   COX         Merged 
 
Figure 10. Dual immunohistochemistry staining of normal pancreas. Block where no 
patches could be seen.  
  
       COX             Amylase             Merged 
 
Figure 11. Dual immunohistochemistry staining of normal pancreas. Green shows COX 
expression and the loss of it in the patch, red shows amylase expression which is reduced 
in the area of the COX-ve patch. Also one cluster of strong COX+ve cells can be seen 




       COX   Amylase        Merged 
 
 
Figure 12. Dual immunohistochemistry staining of normal pancreas. Patch with reduced 
amylase expression (arrow). Of interest, this patch is in close proximity to an islet 
(circled), which produces COX, but not amylase, as expected. 
 
   Amylase   COX         Merged 
 
Figure 13. Dual immunohistochemistry staining of normal pancreas. COX-ve patch with 
mixed amylase expression.   
 
a      b  
Figure 14. Cell morphology viewed using the aqua channel of the fluorescent 
microscope. (a) With the patch with reduced amylase expression in figure 11 (b) with the 
mixed patch shown in figure 12. 
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 Amylase   COX        Merged 
 
Figure 15. Cells expressing COX very strongly in normal pancreas, although 
interestingly these do not express amylase (arrow). 
 
 
Figure 16. Dual immunohistochemistry staining. Ducts are COX+ve (arrow) COX-ve 
(stars) or mixed ( ). 
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4.4 Results for immunohistochemistry for Porin 
The porin staining showed us that the mitochondrial density of the acinar cells in 




Figure 17.  Normal density of mitochondria in comparison to the patch (arrow) where 
less immunoreactivity with the anti-Porin antibody suggests fewer mitochondria. 
 
 30
4.5 Results for immunohistochemistry for COX subunit 1, COX 
subunit IV and Complex II 30 kDa and Complex II 70 kDa 
As expected/predicted the staining for COX complex I and complex IV showed us 
the same patches that we had previously detected when using another antibody for 
the COX complex IV (see figure 18 a-b). But also a patch could be seen when 
staining for Complex II of the respiratory chain, the complex that is totally 
encoded by nuclear DNA (see figure 18 c-d) 
 





c  d  
 
Figure 18. Immunostaining for different parts of the respiratory chain in serial sections 
of the same block that is stained in Figure 18. Arrows show that the patches are clearly 
present for the; (a) COX subunit I (b) COX subunit IV (c) complex II 30 kDa (d) complex 
II 70 kDa. 
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4.6 Results of enzyme histochemistry 
An excellent way to show mtDNA defects is to double stain for COX and SDH. 
Cells that are deficient in COX will still stain positively for SDH. To ensure 
histochemical staining was specific, control experiments were performed on 
frozen pancreas sections, using specific mitochondrial enzyme inhibitors. To 
inhibit COX, sodium azide was used and sodium malonate was used to inhibit 
SDH. This was made as control experiment to confirm that the reaction is specific 
for COX activity and that the negative staining truly does reflect a decrease in 
enzyme activity (see figure 19). 
 
a  b  
 
c  
Figure 19. Photomicrograph of dual COX/SDH histochemistry on human pancreas.  







SC are multipotent cells with the capacity for long-term self-renewal and 
multilineage differentiation and therefore they represent a great source for 
replacement of dysfunctional cells in many diseases; such as β-cells in the 
pancreas for diabetes. However, due to the lack of specific surface markers 
required to isolate these tissue-specific SC cells, their recognition has been limited 
to a few organ systems (Suetsugu et al. 2006). According to two new studies that 
were published recently, there are no SCs in the pancreas. Both of them use 
methods to mark cells and then follow how the marker spreads/dilutes in the 
renewed tissue. Teta et al. (2007) used double labeling via DNA substrates to try 
and show cell lineages descending from SCs. Brennand et al. (2007) looked at 
early postnatal growth using two different approaches to labelling: a histone 
protein that was incorporated into many β-cells and another one that only labelled 
a few cells. Their conclusion was that neither could show signs that progenitor 
cells do exist. Both studies came to the conclusion that all β-cells are equally 
competent in proliferating. In this study we used human adult pancreata in order 
to investigate whether we could follow cell lineage progression via mtDNA 
mutations that occur naturally in our cells as we age. We used COX deficiency as 
our marker of mtDNA mutations as this is readily detected histologically, and has 
been used with great success previously in the human colon (Taylor et al. 2003, 
Greaves et al. 2006). We showed patches of COX deficient cells in the pancreas 
using the same method that Greaves et al. (2006) used to show the existence of 
SCs in the colon. Interestingly, though we didn’t see the same need for a certain 
level of age of a patient for these mutations to become detectable. It is known that 
a certain percentage of the mitochondria in one cell has to be mutated in order for 
it to be detected phenotypically. Taylor et al. (2003), demonstrated that human 
colonic crypts can be a mixture of COX+ve and COX-ve cells. Greaves et al. 
2006 claimed that COX mutations only reached a detectable level of heteroplasmy 
in the colon in patient greater than 40 years of age. The tissues that we chose 
blindly, according to the presence of patches were actually from patients between 
21 and 72 years of age. From the initial results of the immunohistochemical 
analyses it appeared that clonal division from a SC was very likely to be the cause 
of the appearance of COX-ve patches, as they showed the same phenotype, not 
just for mutations in the COX complex but also for mutations in the second 
complex of the respiratory chain. The immunohistochemistry showed COX+ve 
cells within the negative patches. The reason for these could be that they either 
express the wildtype COX complex or that they are heterogeneous, containing 
both wild type and COX-ve mitochondria although at a level that is too low to be 
detectable by this method. Unfortunately in the present study we were not able to 
complete the sequencing of the mtDNA to prove the clonal origins of these cells 
in the patches but this will be done in further work.  
 
It was vital to test that COX-ve cells were functionally normal. Therefore we 
investigated whether COX-ve pancreatic cells were functionally similar to their 
wild type counterparts. Ki-67 is a prognostic marker for some human cancers as it 
can be detected in nuclei undergoing interphase i.e. is present during all active 
phases of the cell cycle (G1, S, G2) but absent during cell arrest (G0). We showed 
Ki-67 was not present in an increased number of COX-ve cells compared to 





Our staining to show the normal synthetic function of the COX-ve cells didn’t 
give us the results we had expected. However they are still very interesting and 
have given, rise to several further studies, outlined below. We showed that COX-
ve cells in the exocrine pancreas produce variable amounts of amylase and thus 
may have reduced enzyme production and function. Slides are currently being 
stained to see if trypsinogen production is affected in these cells, another measure 
of pancreatic exocrine cell function. We next stained for mitochondrial loading, 
i.e. using an antibody for mitochondrial porin (VDAC). Porins are proteins which 
cross a cellular membrane and act as a pore through which molecules can diffuse. 
They are prevalent in the outer membrane of the mitochondria and Gram-negative 
bacteria. In the same series we stained with antibodies for complex II, the so-
called SDH complex in the respiratory chain. The results from this showed us that 
not only the COX complex, but also the SDH complex was affected. This was not 
expected as all subunits in that complex are encoded for by nuclear DNA and 
therefore shouldn’t be affected by mtDNA mutations. If this shown pattern is due 
to less mitochondrial loading or due to mutations in the DNA (either mtDNA or 




Using mtDNA mutations to track cells with related progeny it was possible to 
identify clonal units within the human pancreas. We observed clusters of cells 
with the same phenotype, i.e. altered COX expression. This is strong evidence that 
these patches of cells are a result of proliferation from a common progenitor. Our 
results showed that the COX-ve cells in these patches had abnormal function in 
their reduced production of enzymes, although as these cells are the same 
phenotype, this in fact supports our theory that COX-ve patches are clonal 
proliferation. This theory would be further supported by sequencing the mtDNA 
from multiple cells within a COX-ve patch, and showing that each cell has an 
identical mutation. When we apply this to the odds ratio theory, it would be 
virtually impossible for these cells to have the same mutation without being 
related. Due to time constraints, I was unable to complete this sequencing work, 
although it is currently underway in the lab. 
 
Further work within this field could lead to a useful means of studying pancreatic 
diseases e.g. changes in cell proliferation, migration of cancer, and identification 
of the site of origin of a clone of mutated cells. 
 
 
5.2 Further studies 
Sequencing will be done to see if clonality is the cause of these cells having the 
same COX expression. The case of two cells having the same mutation at the 
same position by chance or by a random event is very small and as said in 
Greaves et al. (2006), this fact can be demonstrated via calculating odds ratio for 
this event to occur. This is done by taking the amount of base pairs multiplied 
times 3 possible transition mutations.  As DNA is double-stranded it has to be 
calculated for two strands and that gives us the following set up: (16,600 x 3) x 
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(16,600 x 3) making 2.48 x 109:1 being the odds ratio. This calculation does not 
take into account mutations that are due to insertion or deletion as it is not 
possible using a set factor for these events to occur.  
 
3D modelling, as described by Taylor et al. (2003) in the human colon, will be 
continued in the lab so that the shape and movement as well as the interaction of 
the patch with surrounding structures can be visualized in the pancreas. Studies 
will continue to look at the strong COX+ve cells, e.g. possible endocrine 
progenitor cell function. As seen in figure 16 these cells don’t produce amylase, 
although resemble acinar cells morphologically. So it would be very interesting to 
see what their synthetic production is, e.g. if they express insulin.  
 
Pancreatic carcinoma has a large mortality rate, thus if  a putative SC population 
can be identified in the pancreas, it will allow novel and specific therapeutic 
targeting as well as provide an alternative source of functional and viable β-cells 
for diabetic patients, thus helping millions of people worldwide. The techniques 
used in this study were proposed to work in any tissues that contain mitochondria, 
to show a novel way of tracing cells of related origin. This study didn’t give us the 
expected results, but if the continued work with sequencing shows that the cells 
are clonal then maybe this staining might be a way of showing cells in a pre-




As work was performed on human tissues ethical approval was required to use 
diagnostic blocks. Therefore we were limited in the amount of sections we could 
get from each block. Some of the tissues that contained patches we were unable to 
get more sections from to continue our work. Ongoing sequencing is being done 
on frozen tissues, whilst the immunostaining was done in paraffin sections. So we 
will never be able to prove that the findings we have in the sequencing will be the 
same mutation in the paraffins, unless we manage to get both frozen and paraffin 
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